Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16342011rdf:typepubmed:Citationlld:pubmed
pubmed-article:16342011lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:16342011lifeskim:mentionsumls-concept:C0011627lld:lifeskim
pubmed-article:16342011lifeskim:mentionsumls-concept:C0011603lld:lifeskim
pubmed-article:16342011lifeskim:mentionsumls-concept:C0162820lld:lifeskim
pubmed-article:16342011lifeskim:mentionsumls-concept:C0006351lld:lifeskim
pubmed-article:16342011lifeskim:mentionsumls-concept:C1314792lld:lifeskim
pubmed-article:16342011lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:16342011lifeskim:mentionsumls-concept:C0021419lld:lifeskim
pubmed-article:16342011lifeskim:mentionsumls-concept:C0205214lld:lifeskim
pubmed-article:16342011pubmed:issue50lld:pubmed
pubmed-article:16342011pubmed:dateCreated2005-12-12lld:pubmed
pubmed-article:16342011pubmed:abstractTextBufexamac is a non-steroidal, anti-inflammatory drug used in the topical treatment of atopic dermatitis, stasis dermatitis and perianal eczema. The substance is known to cause severe allergic contact dermatitis (ACD) as an adverse effect (AE), which may be indistinguishable from the eczema which is to be treated. Hence the diagnosis of this AE is often considerably delayed. In order to estimate the quantitative importance of ACD to bufexamac, data of the Information Network of (German) Departments of Dermatology (IVDK) from July 1999 to December 2004 were analysed.lld:pubmed
pubmed-article:16342011pubmed:languagegerlld:pubmed
pubmed-article:16342011pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16342011pubmed:citationSubsetIMlld:pubmed
pubmed-article:16342011pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16342011pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16342011pubmed:statusMEDLINElld:pubmed
pubmed-article:16342011pubmed:monthDeclld:pubmed
pubmed-article:16342011pubmed:issn0012-0472lld:pubmed
pubmed-article:16342011pubmed:authorpubmed-author:GefellerOOlld:pubmed
pubmed-article:16342011pubmed:authorpubmed-author:SchnuchAAlld:pubmed
pubmed-article:16342011pubmed:authorpubmed-author:UterWWlld:pubmed
pubmed-article:16342011pubmed:issnTypePrintlld:pubmed
pubmed-article:16342011pubmed:day16lld:pubmed
pubmed-article:16342011pubmed:volume130lld:pubmed
pubmed-article:16342011pubmed:ownerNLMlld:pubmed
pubmed-article:16342011pubmed:authorsCompleteYlld:pubmed
pubmed-article:16342011pubmed:pagination2881-6lld:pubmed
pubmed-article:16342011pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:16342011pubmed:meshHeadingpubmed-meshheading:16342011...lld:pubmed
pubmed-article:16342011pubmed:meshHeadingpubmed-meshheading:16342011...lld:pubmed
pubmed-article:16342011pubmed:meshHeadingpubmed-meshheading:16342011...lld:pubmed
pubmed-article:16342011pubmed:meshHeadingpubmed-meshheading:16342011...lld:pubmed
pubmed-article:16342011pubmed:meshHeadingpubmed-meshheading:16342011...lld:pubmed
pubmed-article:16342011pubmed:meshHeadingpubmed-meshheading:16342011...lld:pubmed
pubmed-article:16342011pubmed:meshHeadingpubmed-meshheading:16342011...lld:pubmed
pubmed-article:16342011pubmed:meshHeadingpubmed-meshheading:16342011...lld:pubmed
pubmed-article:16342011pubmed:meshHeadingpubmed-meshheading:16342011...lld:pubmed
pubmed-article:16342011pubmed:meshHeadingpubmed-meshheading:16342011...lld:pubmed
pubmed-article:16342011pubmed:meshHeadingpubmed-meshheading:16342011...lld:pubmed
pubmed-article:16342011pubmed:meshHeadingpubmed-meshheading:16342011...lld:pubmed
pubmed-article:16342011pubmed:meshHeadingpubmed-meshheading:16342011...lld:pubmed
pubmed-article:16342011pubmed:meshHeadingpubmed-meshheading:16342011...lld:pubmed
pubmed-article:16342011pubmed:meshHeadingpubmed-meshheading:16342011...lld:pubmed
pubmed-article:16342011pubmed:meshHeadingpubmed-meshheading:16342011...lld:pubmed
pubmed-article:16342011pubmed:meshHeadingpubmed-meshheading:16342011...lld:pubmed
pubmed-article:16342011pubmed:meshHeadingpubmed-meshheading:16342011...lld:pubmed
pubmed-article:16342011pubmed:meshHeadingpubmed-meshheading:16342011...lld:pubmed
pubmed-article:16342011pubmed:meshHeadingpubmed-meshheading:16342011...lld:pubmed
pubmed-article:16342011pubmed:meshHeadingpubmed-meshheading:16342011...lld:pubmed
pubmed-article:16342011pubmed:year2005lld:pubmed
pubmed-article:16342011pubmed:articleTitle[A common and insidious side-effect: allergic contact dermatitis caused by bufexamac used in the treatment of dermatitis. Results from the Information Network of Departments of Dermatology (IDVK)].lld:pubmed
pubmed-article:16342011pubmed:affiliationZentrale des IVDK, Institut an der Universität Göttingen, Göttingen. aschnuch@med.uni-goettingen.delld:pubmed
pubmed-article:16342011pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16342011pubmed:publicationTypeEnglish Abstractlld:pubmed